Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
688566 Jiangsu Jibeier Pharmaceutical Co., Ltd.
- 24.28
- +0.75+3.19%
Market Closed Apr 24 15:00 CST
4.84BMarket Cap22.38P/E (TTM)
24.81High23.41Low35.55KlotVolume23.52Open23.53Pre Close86.33MTurnover1.78%Turnover Ratio22.07P/E (Static)199.43MShares29.6852wk High2.11P/B4.84BFloat Cap18.3652wk Low28.24Limit Up199.43MShs Float53.01Historical High18.82Limit Down5.95%Amplitude13.74Historical Low0.52Dividend TTM24.28Avg Price16.08KlotAsk2.14%Div YieldTTM100Lot Size17.90KlotBid
Jiangsu Jibeier Pharmaceutical Co., Ltd. Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Money funds | 29.97%627.55M | 21.96%847.48M | 21.56%630.01M | 12.39%836.03M | -33.20%482.85M | -23.13%694.87M | -32.79%518.28M | -27.23%743.86M | 39.84%722.82M | -11.82%903.9M |
| Transactional financial assets | 1.36%299M | 60.00%56M | 40.85%331M | 125.00%135M | 55.26%295M | -61.11%35M | -27.24%235M | -51.22%60M | -71.21%190M | -55.00%90M |
| Notes receivable and accounts receivable | 0.49%291.4M | -18.53%300.75M | -0.33%320.29M | 16.71%314.74M | 86.05%289.98M | 70.73%369.15M | 107.45%321.34M | 127.55%269.68M | 2.33%155.86M | 47.48%216.21M |
| -Notes receivable | -57.09%35.43M | -78.30%30.44M | -45.60%60.6M | 57.77%55.85M | 178.54%82.57M | 13.50%140.3M | 169.63%111.39M | 94.51%35.4M | -42.97%29.64M | 93.03%123.61M |
| -Accounts receivable | 23.41%255.97M | 18.12%270.31M | 23.69%259.69M | 10.50%258.89M | 64.33%207.41M | 147.14%228.85M | 84.83%209.95M | 133.54%234.28M | 25.79%126.22M | 12.15%92.6M |
| Other receivables (including interest and dividends) | -86.86%71.31K | 16.02%95.11K | 110.62%165.91K | -27.68%71.31K | 370.08%542.61K | 7.62%81.98K | 11.10%78.78K | 30.71%98.6K | 4.83%115.43K | -27.00%76.17K |
| -Other receivable | ---- | 16.02%95.11K | ---- | -27.68%71.31K | ---- | 7.62%81.98K | ---- | 30.71%98.6K | ---- | -27.00%76.17K |
| Advance payment | -39.70%3.47M | 96.22%4.24M | -6.93%4.37M | 41.66%4.54M | 67.29%5.75M | -49.92%2.16M | 37.12%4.7M | 12.58%3.21M | -17.75%3.44M | 71.32%4.31M |
| Inventories | 16.54%35.14M | 4.02%30.7M | -5.26%34.72M | -5.64%30.93M | -22.23%30.15M | -9.63%29.51M | 9.64%36.65M | -10.20%32.79M | 12.50%38.77M | 2.61%32.66M |
| Receivable financing | --54.09M | --65.17M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Other current assets | -99.85%688.74 | -99.82%688.74 | -99.95%688.74 | 2,035.56%8.56M | -11.25%472.39K | -96.07%378.05K | 142,460.99%1.26M | 45,195.52%400.69K | 20,092.65%532.25K | 809,803.93%9.61M |
| Total current assets | 18.64%1.31B | 15.32%1.3B | 18.19%1.32B | 19.81%1.33B | -0.61%1.1B | -10.00%1.13B | -13.11%1.12B | -14.82%1.11B | -18.75%1.11B | -10.62%1.26B |
| Non Current assets | ||||||||||
| Fixed assets | ---- | -11.09%69.24M | ---- | -10.43%73.3M | ---- | -9.30%77.87M | ---- | -10.05%81.84M | ---- | -10.60%85.85M |
| Constru in process | ---- | 21.60%917.62M | ---- | 33.80%795.89M | ---- | 61.81%754.62M | ---- | 92.14%594.84M | ---- | 165.77%466.36M |
| Intangible assets | -2.78%56.29M | -2.61%56.69M | -2.60%57.09M | -2.58%57.49M | -2.56%57.9M | -2.57%58.2M | -2.56%58.61M | -2.42%59.02M | -2.45%59.42M | -2.51%59.74M |
| Development expenditure | --39.86M | --31.76M | --20.72M | --17.94M | ---- | ---- | ---- | ---- | ---- | ---- |
| Long deferred expense | 102.36%1.92M | -66.20%380.59K | -61.82%535.05K | -55.09%735.08K | -50.27%949.52K | -48.39%1.13M | -42.90%1.4M | -39.62%1.64M | -35.99%1.91M | -32.96%2.18M |
| Deferred tax assets | 7.91%17.77M | 11.14%17.93M | -26.24%14.26M | -9.27%17M | -2.60%16.47M | 3.52%16.13M | 30.00%19.33M | 35.06%18.74M | 33.24%16.91M | 33.00%15.59M |
| Other non current assets | 20.55%50.45M | 11.98%49.69M | -25.10%26.74M | 24.73%62.24M | 2.53%41.85M | 171.50%44.38M | 835.19%35.7M | 1,225.54%49.9M | 201.85%40.82M | 99.04%16.34M |
| Total non current assets | 11.78%1.24B | 13.41%1.22B | 16.94%1.17B | 22.79%1.15B | 29.94%1.11B | 52.38%1.08B | 67.54%1B | 74.82%935.23M | 84.69%852.97M | 71.55%707.8M |
| Total assets | 15.21%2.55B | 14.39%2.53B | 17.60%2.49B | 21.17%2.48B | 12.65%2.21B | 12.48%2.21B | 12.48%2.12B | 11.27%2.05B | 7.36%1.96B | 8.02%1.96B |
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Short term loan | 138.32%23.75M | 110.17%20.83M | 947.16%3.1M | --7.18M | 759.13%9.97M | --9.91M | --295.91K | ---- | --1.16M | ---- |
| Notes payable and accounts payable | -3.74%81.33M | 6.50%97.15M | -31.03%70.57M | -12.76%70.6M | 22.63%84.48M | -10.28%91.22M | 24.71%102.32M | -15.22%80.93M | 13.31%68.89M | 45.42%101.67M |
| -Accounts payable | -3.74%81.33M | 6.50%97.15M | -31.03%70.57M | -12.76%70.6M | 22.63%84.48M | -10.28%91.22M | 24.71%102.32M | -15.22%80.93M | 13.31%68.89M | 45.42%101.67M |
| Contract liabilities | -38.57%1.03M | -47.62%948.33K | 35.50%2.18M | -54.29%956.37K | -15.63%1.68M | -47.05%1.81M | 42.22%1.61M | -15.66%2.09M | 74.55%1.99M | 126.89%3.42M |
| Salaries payable | 1.45%10.73M | -17.83%23.79M | 7.66%19.24M | 6.52%14.91M | 6.77%10.58M | 33.99%28.96M | 21.30%17.87M | 17.39%14M | 59.16%9.91M | 10.14%21.61M |
| Taxs payable | 27.06%19.17M | 22.05%19.42M | -7.25%17.35M | -10.51%23.09M | 62.44%15.08M | 57.04%15.91M | 82.19%18.7M | 267.87%25.8M | -24.13%9.29M | -19.21%10.13M |
| Other payable (including interest and dividends) | -40.68%21.87M | -63.17%22.94M | -34.76%29.63M | 28.27%98.08M | -18.69%36.88M | 43.31%62.27M | -40.34%45.42M | 306.87%76.47M | 116.12%45.35M | 114.28%43.45M |
| -Dividend payable | ---- | ---- | ---- | --51.1M | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other payable | ---- | -63.17%22.94M | ---- | -38.56%46.98M | ---- | 43.31%62.27M | ---- | 306.87%76.47M | ---- | 114.28%43.45M |
| Other current liabilities | -38.57%134.01K | -47.62%123.28K | 35.50%282.81K | -84.22%124.33K | -81.17%218.14K | -78.12%235.36K | 42.22%208.71K | 144.34%787.98K | 682.18%1.16M | 448.97%1.08M |
| Total current liabilities | -0.55%158.02M | -11.94%185.19M | -23.64%142.35M | 7.44%214.95M | 15.35%158.89M | 15.96%210.31M | 1.07%186.42M | 47.13%200.07M | 35.66%137.74M | 46.19%181.36M |
| Current liabilities | ||||||||||
| Long term salaries pay | 0.00%26.64M | 0.00%26.64M | 0.00%26.64M | 0.00%26.64M | 0.00%26.64M | 0.00%26.64M | 0.00%26.64M | 0.00%26.64M | 0.00%26.64M | 0.00%26.64M |
| Deferred tax liabilities | 0.00%3.25M | 0.00%3.25M | 0.00%3.25M | 0.00%3.25M | -4.15%3.25M | -4.15%3.25M | --3.25M | --3.25M | --3.4M | --3.4M |
| Long term deferred income | -0.77%58.43M | -0.77%58.59M | -0.37%58.55M | -0.38%58.72M | -0.36%58.88M | 0.33%59.04M | -0.12%58.77M | -0.53%58.94M | -0.65%59.09M | -1.42%58.85M |
| Total non current liabilities | -0.51%88.32M | -0.51%88.48M | -0.25%88.44M | -0.25%88.61M | -0.39%88.77M | 0.06%88.94M | 3.73%88.66M | 3.42%88.83M | 3.50%89.12M | 2.95%88.88M |
| Total liabilities | -0.53%246.34M | -8.55%273.68M | -16.10%230.79M | 5.07%303.56M | 9.17%247.66M | 10.73%299.25M | 1.91%275.09M | 30.21%288.9M | 20.90%226.87M | 28.45%270.24M |
| Shareholders equity | ||||||||||
| Paid-in capital | 5.47%199.43M | 5.47%199.43M | 5.47%199.43M | 5.13%196.53M | 1.15%189.08M | 1.15%189.08M | 1.15%189.08M | 0.00%186.94M | 0.00%186.94M | 0.00%186.94M |
| Capital reserve funds | 19.77%1.3B | 20.06%1.3B | 20.35%1.3B | 20.45%1.27B | 3.55%1.08B | 3.84%1.08B | 4.11%1.08B | 2.08%1.05B | 2.10%1.05B | 2.11%1.04B |
| Surplus reserve funds | 5.47%99.72M | 5.47%99.72M | 0.00%94.54M | 1.15%94.54M | 1.15%94.54M | 5.17%94.54M | 15.14%94.54M | 18.92%93.47M | 21.25%93.47M | 21.33%89.9M |
| Retained profit | 18.30%699.59M | 20.64%650.06M | 39.48%662.32M | 46.19%609.76M | 46.48%591.37M | 45.92%538.85M | 57.41%474.83M | 33.31%417.1M | 16.77%403.71M | 15.35%369.28M |
| Shareholders equity without minority interests | 17.26%2.3B | 18.05%2.25B | 22.71%2.26B | 23.91%2.17B | 13.17%1.96B | 12.82%1.9B | 14.33%1.84B | 8.73%1.75B | 5.86%1.73B | 5.40%1.69B |
| Minority interests | -6.38%5.15M | -6.31%5.23M | -5.19%5.33M | -5.18%5.41M | -5.21%5.5M | -5.43%5.58M | -6.18%5.62M | -6.33%5.71M | -6.38%5.8M | -6.42%5.9M |
| Total shareholder equity | 17.19%2.3B | 17.98%2.25B | 22.63%2.26B | 23.82%2.17B | 13.11%1.97B | 12.75%1.91B | 14.25%1.84B | 8.67%1.76B | 5.81%1.74B | 5.35%1.69B |
| Total liabilityies and equity | 15.21%2.55B | 14.39%2.53B | 17.60%2.49B | 21.17%2.48B | 12.65%2.21B | 12.48%2.21B | 12.48%2.12B | 11.27%2.05B | 7.36%1.96B | 8.02%1.96B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | -- | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs